Social Media Ideas for Alny

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Amyloidosis Continues To Fight Back

<![CDATA[Pharmaceutical Executive Daily: Alnylam Pharmaceuticals and Inceptive Nucleics Announce 3 Year Strategic Col...

<![CDATA[Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive ]]>

Astellas Pharma Inc. (ALPMY) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow

City banks nearly $100M for next-gen RNAi drugs

Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon fol...

Alnylam, Inceptive ink AI deal potentially worth $2B

The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.

Expansion

Expansion Anonymous (not verified) Mon, 06/29/2026 - 03:04 field_thread_url https://cafepharma.com/boards/threads/expansion.701787/ boar...

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

Expansion

Expansion Anonymous (not verified) Thu, 06/25/2026 - 03:02 field_thread_url https://cafepharma.com/boards/threads/expansion.701787/ boar...

Allient Inc. (ALNT) Presents at Northland Growth Conference 2026 - Slideshow

Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation

Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer

Alnylam has partnered with the person who helped put the “T” in ChatGPT, paying $30 million to work with Jakob Uszkoreit’s Inceptive Nucleics on artificial intelligence-enabled dru...

Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.

Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare H...

<![CDATA[AlzeCure Enters $1 Billion Collaboration and Out-Licensing Agreement with Eli Lilly ]]>

Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio

<![CDATA[Ascidian and Eli Lilly Enter $1.9 Billion Global Research Collaboration to Develop RNA Exon Editors]]>

Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class

Lilly moves deeper into Alzheimer’s research with AlzeCure licensing deal

Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease from AlzeCure Pharma for up to $1 billion biobucks.

Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event -...

AstraZeneca, Ionis drug fails big heart disease study in major setback

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio...

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval

This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.